» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 129 | NO. 39 | Wednesday, February 26, 2014

Lilly Diabetes Drug Meets Late-Stage Goal

AP

Print | Front Page | Email this story | Comments ()

INDIANAPOLIS (AP) – Eli Lilly and Co.'s experimental injectable diabetes treatment dulaglutide fared on par in a late-stage study with another drug that's already on the market.

The Indianapolis drugmaker said Tuesday that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment. A non-inferior finding essentially means that the drug did not show superiority or inferiority to the other treatment. That determination was the main goal of the study.

The study measured blood sugar reductions for patients with type 2 diabetes. Lilly plans to present more details on that study and other trials involving dulaglutide later this year at scientific meetings.

The drugmaker has conducted six late-stage studies on dulaglutide and submitted it for marketing approval to regulators in both the United States and Europe. Lilly is counting on potential new drugs like this to help counter revenue hits it is taking due to the loss of patents protecting key products like the antidepressant Cymbalta from cheaper generic competition.

Type 2 is the most common form of diabetes, a chronic disease that occurs when the body doesn't properly produce or use the hormone insulin. Diabetes treatments represent a large slice of Lilly's product portfolio, which includes the insulins Humalog and Humulin.

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog Get more from The Daily News
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 92 388 9,204
MORTGAGES 119 513 12,365
FORECLOSURE NOTICES 0 98 2,526
BUILDING PERMITS 0 960 20,801
BANKRUPTCIES 77 338 7,964
BUSINESS LICENSES 14 91 3,315
UTILITY CONNECTIONS 180 695 11,718
MARRIAGE LICENSES 33 147 2,815

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.